Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2

Verhoog, L. C., Brekelmans, C.T.M., Seynaeve, C., Dahmen, G., van Geel, A. N., Bartels, C.C.M., Tilanus-Linthorst, M.M.A., Wagner, A., Devilee, P., Halley, D.J.J., van den Ouweland, A.M.W., Meijers-Heijboer, E. J., Klijn, J.G.M. · 1999 · Journal of Clinical Oncology

Abstract

PURPOSE: Breast cancer in BRCA1 and BRCA2 gene-mutation carriers may differ from so-called sporadic breast cancer in clinical features and behavior. These potential differences may be of importance for the prevention, screening, and, ultimately, treatment of breast cancer in women with such germline mutations. Thus far, there have been very few studies on the survival of BRCA2-associated breast cancer patients. PATIENTS AND METHODS: We determined the disease-free and overall survival of 28 breast cancer patients from 14 consecutive families with eight different BRCA2 germline mutations. These patients' survival and tumor characteristics were compared with those of a control group of 112 sporadic breast cancer patients matched to them by age and year of diagnosis. RESULTS: The 5-year disease-free survival was 52% for each group (P = .91); the overall survival was 74% for BRCA2 carriers and 75% for sporadic cases (P = .50). At the time of diagnosis, tumors from the BRCA2 carriers were borderline significantly larger in comparison to the tumors in sporadic cases (P = .05), but axillary nodal status was not significantly different in the two groups (node-negativity, 63% v 52.8%, respectively; P = .34). With respect to steroid receptor status, BRCA2-associated tumors were more likely to be steroid receptor-positive, especially regarding progesterone receptor status (100% v 76.7% positive, respectively; P = .06). Stage-adjusted recurrence and death rates were nonsignificantly better for BRCA2 cases (hazard ratios of 0.84 and 0.59 [P = .61 and P = .19], respectively). In contrast, after 5 years, the rate of metachronous contralateral breast cancer in BRCA2 patients was 12% (v 2% in controls; P = .02). CONCLUSION: Patients with hereditary breast cancer due to BRCA2 have a similar prognosis when compared with age-matched sporadic breast cancer patients. Contrary to our previous observation regarding BRCA1-associated breast cancer, BRCA2 tumors tended to be steroid receptor-positive, instead of steroid receptor-negative.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1999.17.11.3396

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 31

  1. 10.1126/science.7545954 · DOI · Paper page
  2. 10.1038/378789a0 · DOI · Paper page
  3. 10.1056/NEJM199705153362001 · DOI · Paper page
  4. 10.1086/301749 · DOI · Paper page
  5. 10.1200/JCO.1998.16.5.1969 · DOI · Paper page
  6. 10.1002/1097-0142(197112)28:6<1500::AID-CNCR2820280623>3.0.CO;2-D · doi:10.1002/1097-0142(197112)28:6<1500::aid-cncr2820280623>3.0.co;2-d
  7. 10.1126/science.2270482 · DOI · Paper page
  8. 10.1038/sj.bjc.6690235 · DOI
  9. 10.1023/A:1005853022804 · DOI
  10. 10.1016/S0140-6736(96)10109-4 · DOI · Paper page
  11. 10.1016/S0046-8177(98)90427-0 · DOI
  12. 10.1093/jnci/90.15.1138 · DOI · Paper page
  13. Lynch HT, Albano WA, Recabaren JA, et al: Survival in hereditary breast and colon cancer. JAMA 246:1197,1981, (letter) · DOI
  14. 10.1007/BF01806526 · DOI
  15. 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.0.CO;2-H · DOI
  16. 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W · DOI · Paper page
  17. 10.1016/S0140-6736(98)22005-8 · DOI
  18. 10.1016/S0167-8140(98)00023-1 · DOI
  19. 10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N · DOI
  20. 10.1093/jnci/91.3.259 · DOI
  21. 10.1016/S0140-6736(05)79248-5 · DOI
  22. 10.1002/bjs.1800811038 · DOI
  23. 10.1200/JCO.1998.16.5.1642 · DOI · Paper page
  24. 10.1038/ng0596-117 · DOI · Paper page
  25. 10.1086/301885 · DOI · Paper page
  26. Osin P, Crook T, Powles T, et al: Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet 351:1487,1998, (letter) · DOI
  27. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 229:424,1998-428, · DOI · Paper page
  28. 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W · DOI · Paper page
  29. 10.1016/S0959-8049(98)00248-2 · DOI
  30. 10.1093/jnci/90.18.1371 · DOI · Paper page
  31. 10.1097/00000658-197008000-00013 · doi:10.1097/00000658-197008000-00013

Cited by

See all 175

Metadata

Authors
Verhoog, L. C., Brekelmans, C. T. M., Seynaeve, C., Dahmen, G., van Geel, A. N., Bartels, C. C. M., Tilanus-Linthorst, M. M. A., Wagner, A., Devilee, P., Halley, D. J. J., van den Ouweland, A. M. W., Meijers-Heijboer, E. J., & Klijn, J. G. M.
Venue
Journal of Clinical Oncology
Published
1999-11
Volume
17
Issue
11
Pages
3396-3402
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1932411143
Cited by
175
References
3
FWCI
9.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2. https://app.cochat.ai/papers/10.1200/jco.1999.17.11.3396
The paper
Verhoog, L. C., Brekelmans, C. T. M., Seynaeve, C., Dahmen, G., van Geel, A. N., Bartels, C. C. M., Tilanus-Linthorst, M. M. A., Wagner, A., Devilee, P., Halley, D. J. J., van den Ouweland, A. M. W., Meijers-Heijboer, E. J., & Klijn, J. G. M. (1999). Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.11.3396

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.